Jaewon Ryu, M.D., J.D., sees prevention and early recognition of disease as central to value-based care practices and ...

With the advent of the ACO programs 15 years ago — Medicare Shared Savings Program was launched as part of the implementation ...

Delaying onboarding until FDA approval reduces sunk-cost risk but can impede institutional learning and slow post-approval ...

In an hour and 48-minute speech that set the record for length for the State of the Union address, President Donald Trump ...

Successful program buildout prioritizes defined patient flow, infusion access, cold-chain capabilities, and accountability ...

According to the Gallup National Health and Well-Being Index, 37% of U.S. adults now report obesity, down from 39.9% three ...

A custom NGS panel covering 27 IARC carcinogenic HPV genotypes enabled detection of ccfHPV DNA across treatment strata and ...

New phase 4 data from Vertex Pharmaceuticals revealed that more than 90% of patients recovering from aesthetic or reconstructive surgery remained opioid-free when treated with Journavx (suzetrigine) ...

Modeling at 2023 net pricing estimated semaglutide would avert >358,000 cardiovascular events/deaths, saving ~$15B in cardiovascular care plus ~$8B in other care, but adding ~$344B lifetime drug spend ...

Navitus Health Solutions’ Pulse Survey questioned 2,000 Americans who are taking or have taken GLP-1 medications in the last two years. GLP-1s include semaglutide (Ozempic for diabetes and Wegovy for ...

Risant’s CEO Jaewon Ryu discusses some of the early success of bringing a set of Kaiser Permanente’s value-based care ...

A study published this week found that Black Medicare beneficiaries with early-stage NSCLC remain significantly less likely than White beneficiaries to receive curative treatment, largely because of ...